Temozolomide

For research use only.

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856,TMZ

103 publications

Temozolomide Chemical Structure

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) JPY 13376.00 In stock
JPY 13600.00 In stock
JPY 30200.00 In stock
JPY 146400.00 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Temozolomide has been cited by 103 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPJdVBpPDhiaB?= NVLpRnZRUUN3ME2xN|kvOjEkgJpCtgKBkTVwOUWg{txO M3fMSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
KellyCis83 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:yNVRPPDhiaB?= Mn7kTWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> MmjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
SK-N-AS NUfSV4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvpOFghcA>? NV21d2g{UUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>? M2ToUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
SK-N-ASCis24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq0PEBp M{jrWGlEPTB;NEiwMlYx6oDLwsJihKkyODFwMUWg{txO MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
CHP-212 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfpeZA1QCCq MW\JR|UxRTdwOUhihKnDueLCiUCuOlkh|ryP M123Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
CHP-212Cis100 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zSW|Q5KGh? NEPNWGdKSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN NWrsZoJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
U87  MWXGeY5kfGmxbjDBd5NigQ>? M4PKSFExOCEQvF2= MWKyOE04OiCq NHTBOI9qdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= Ml\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEi4OlgoRjJ3OEC4PFY5RC:jPh?=
LN229 NGnsWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[wMVUxKM7:TR?= NVHjbZgxUUN3ME2xOkDPxE1? NUXRNJlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVAzPzNpPkK1O|UxOjd|PD;hQi=>
TR-LN229 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETTSXgxNTVyIN88US=> MYLJR|UxRTd5IN88US=> MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUCyO|MoRjJ3N{WwNlc{RC:jPh?=
U87  M2D3NGFxd3C2b4Ppd{BCe3OjeR?= M13lRVDjiJN{MEFihKnDvU1? M{\6bFI1KGh? MUXlcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MU[2PEc,OjV4OEG2Olg9N2F-
U251MG NFvTNnFCeG:ydH;zbZMhSXO|YYm= NFjFSYoyODEEoN88US=> M4X1bVQ5KGh? MmCyVGJU NYLNRYRZcW6mdXPld{BieG:ydH;zbZM> MnniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OEC0OlQoRjJ3NkiwOFY1RC:jPh?=
U87MG M{LC[GFxd3C2b4Ppd{BCe3OjeR?= NIjZU4YyODEEoN88US=> NGHhSpI1QCCq NXz5O5NJWEKV NGLRcGhqdmS3Y3XzJIFxd3C2b4Ppdy=> NGDkfnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87 NILKd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2VXY2OC1|NUCg{txO NFrXPY41QMLiaNMg MkLrbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NGTDUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U118  MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXBOVAuOzVyIN88US=> NEDrW2Y1QMLiaNMg NIfVclJqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? M2\JSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
U87 M2\ufGZ2dmO2aX;uJGF{e2G7 NFvZO3IzPTBxM{WwJO69VQ>? M3HMZ|Q5yqCqwrC= NHLte5JmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U118  MYjGeY5kfGmxbjDBd5NigQ>? NILNVYszPTBxM{WwJO69VQ>? M{fzc|Q5yqCqwrC= M2O2VYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U87 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17mSVI2OC9|NUCg{txO M13GbVQ5yqCqwrC= NV;KPXhKcW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?= NWrwVZVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVQzOjNpPkK1OVU1OjJ|PD;hQi=>
A375 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi2NY9kPDkEoHlCpC=> NVnsdmhJUUN3ME2yOlUh|ryP NEDLNpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
A2058 NVnHb5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LYeFQ5yqCqwrC= MWnJR|UxRTF{IN88US=> MljPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M238 NWnHb5dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M134ZVQ5yqCqwrC= NYe4VIdNUUN3ME20NEDPxE1? NHfCSoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
M249 NISyOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXi0POKhcMLi M4PndWlEPTB;MkW0JO69VQ>? Mlu5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M21 M4TLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF74V5c1QMLiaNMg NV3PcmZoUUN3ME2yNlEh|ryP MmPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
U251 MnfoR5l1d3SxeHn0fUBCe3OjeR?= MX2yNEDPxE4EoB?= MlXCOFjDqGkEoB?= MXTy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm NIjGcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFM5OSd-MkW0N|Q{QDF:L3G+
LN229 MmTTR5l1d3SxeHn0fUBCe3OjeR?= MX2yNEDPxE4EoB?= NYTvd25vPDkEoHlCpC=> MYPy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm NFXCNHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFM5OSd-MkW0N|Q{QDF:L3G+
U373MG-LUC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW3NkBp M3LvUmlEPTB-NkCwJO69VQ>? NXuyNmNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|E6PTNpPkK1OFMyQTV|PD;hQi=>
U87  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILNZpozPS1{MECg{txO MmDUOFjDqGkEoB?= NWqyfnJ7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyMEe0OUc,OjV2MEC3OFU9N2F-
U251 M1HRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnTNlUuOjByIN88US=> MWC0POKhcMLi MlG0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NInxS5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwNFc1PSd-MkW0NFA4PDV:L3G+
U251 NFzKUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PBb|ExOC12MECg{txO NHzHWJE4Oi97NjDo NELXe2h1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= NXzOSJk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO|UzPzFpPkK1N|c2OjdzPD;hQi=>
U373 NGH2NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfxNVAxNTRyMDFOwG0> MUi3Nk86PiCq MUn0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5NUK3NUc,OjV|N{WyO|E9N2F-
U343 NUfONWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW1NVAxNTRyMDFOwG0> MlfVO|IwQTZiaB?= NGXaOVB1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= NEHFOFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO|UzPzF:L3G+
U87MG-luc2 NWfTcmdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi1R3d6OTByLUSwNEDPxE1? MUC3Nk86PiCq MoWzeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi Ml7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|N{WyO|EoRjJ3M{e1NlcyRC:jPh?=
U87 MVrGeY5kfGmxbjDBd5NigQ>? MmflNlAxKM7:TR?= M4q5RlQ5KGh? MlH4bY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NXHRdow{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U251 MmPUSpVv[3Srb36gRZN{[Xl? MUOyNFAh|ryP MVi0PEBp NWHkXYl3cW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|N{eyNUc,OjV|M{e3NlE9N2F-
A172 MYDGeY5kfGmxbjDBd5NigQ>? NX\IPIdWOjByIN88US=> M2TZZ|Q5KGh? NH7UW5RqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w NHW5OZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO|czOSd-MkWzN|c4OjF:L3G+
U251 NIPwVZlHfW6ldHnvckBCe3OjeR?= M{C0dFIxOCEQvF2= NYfaVoZlPDhiaB?= MoPkbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MoHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{e3NlEoRjJ3M{O3O|IyRC:jPh?=
A172 MUXGeY5kfGmxbjDBd5NigQ>? NWHzcVNDOjByIN88US=> MVS0PEBp NV;0b5U2cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= NW\1Ond{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U87 MV7GeY5kfGmxbjDBd5NigQ>? M1zJb|IxOCEQvF2= NV7PcW1OOjRxN{KvNVIxKGh? M13JXIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? NYDIPVMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U251 NGrKUW1HfW6ldHnvckBCe3OjeR?= NE[4SGUzODBizszN MmqwNlQwPzJxMUKwJIg> M2HkZYlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? M2X0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O|IyLz5{NUOzO|czOTxxYU6=
A172 NYXSWI5{TnWwY4Tpc44hSXO|YYm= M4jp[VIxOCEQvF2= MUeyOE84Oi9zMkCgbC=> NW\5cZJwcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 M{\pe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O|IyLz5{NUOzO|czOTxxYU6=
SNB19V M4WzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK3JIQ> MlLNSG1UVw>? NXPKUY5{T0l3ME2zOU44yrFzMjFOwG0> NWnqd4RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19M Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132Wlch\A>? MUXEUXNQ MnL0S2k2OD12NkmuPeKyQDhizszN NUPGT4pjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19VR NYf4dGJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3JIQ> Mk\6SG1UVw>? MYfHTVUxRTJ6MD6yxtEyQCEQvF2= NVLJflJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
U373V MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPsZmc4KGR? NVnafm5OTE2VTx?= MlfPS2k2OD14OD6wxtE{OiEQvF2= M4jURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
U373M MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHyO{Bl NGq3T4NFVVOR MVHHTVUxRTN4OD63xtE5PiEQvF2= NU\0b|d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
U373VR NU[0XlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W3UFch\A>? M3rQb2ROW09? NIfaRm9IUTVyPUK4PE45yrF|MzFOwG0> Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U87MG M2C1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W4O|ch\A>? MV7EUXNQ MYfHTVUxRTN6LkRCtVIxKM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
HCT116 NY[0Noc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GzS|ch\A>? NVjmW5l[TE2VTx?= M4K3bGdKPTB;NUe5MlnDuTN{IN88US=> M{XQc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
DLD1 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm3JIQ> M4XuV2ROW09? NVXDWIhIT0l3ME21NFEvPMLzOUOg{txO M1fQS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
MRC5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f2Xlch\A>? MX\EUXNQ MorqS2k2OD12NEmuOOKyQCEQvF2= MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19V  NXj2TWR6TnWwY4Tpc44hSXO|YYm= MonMNVAxKM7:TdMgWG1b MUSwMVczKGh? MlXubY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> MnroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
T98G  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV21M|ExNzF3IN88US=> NI\OPI4zPMLiaB?= NGmxdnVqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> MoX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U251  MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzXdmx[PS9zMD:xOUDPxE1? MYSyOOKhcA>? NGjIWGdqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
T98G  MXnGeY5kfGmxbjDBd5NigQ>? NE\qfZQyPSEQvF2= NYCxOnk{OjUEoHi= MYLpcoNz\WG|ZYOgSG5CNW[{YXft[Y51[XSrb36gbY4hVlCnNj3QSHQhfHKnYYTl[EBodGmxbXGgZ4VtdHN? NXjSOGNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
U251  MYnGeY5kfGmxbjDBd5NigQ>? MoLNNVUh|ryP Ml;3NlTDqGh? M4PhS4lv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= MojZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U-87 MG NILqUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XlNlczKGh? NF;vWmNKSzVyPUCuPVMhdU4EoB?= NXjBNWhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U-118 MG NUjGdm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjQO|IhcA>? M2HvTWlEPTB;MT6wOUBuVcLi NG\ZOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0OVM{Oid-MkWyOFU{OzJ:L3G+
U87 NIC2dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSyOEBp NV7lZ3BWUUN3ME2yOlAvOzRizszNxsA> M1jsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUezNlM{Lz5{NUG3N|I{OzxxYU6=
U87 GSLCs NVf1Sok4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\UPVI1KGh? NXLSWo43UUN3ME23OlYvOTFizszNxsA> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5M{KzN{c,OjVzN{OyN|M9N2F-
U87MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;hR45UPzJiaB?= MVrJR|UxRTF3Lk[yOUDPxE4EoB?= M3XkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwPVE2Lz5{NUC1NFkyPTxxYU6=
U251 NVHobVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnISGQ1OTByLUSwNEDPxE1? MmPwOFghcA>? NEHsWmdFVVOR Mnv2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4TLS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
U87 NH;WT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXWNVAxNTRyMDFOwG0> MUO0PEBp M1W5VGROW09? M{DGOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
MDA-MB-231-br M1HUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrp[pExNTFyIN88US=> MVi0PEBp MlTYSG1UVw>? NYTtWHhtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUOzeGQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
HCC-1937 NIPNe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPLT4ZkOC1|MECg{txO M3\tXVQ5KGh? Ml;SSG1UVw>? NXm4UIVEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
MDA-MB-231 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPVNE01OCEQvF2= MnnJOFghcA>? NX3KdY5FTE2VTx?= NXHFOVZocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1PneFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
MDA-MB-468 M1rDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLvNE02ODBizszN M4rF[FQ5KGh? NYTJe|dTTE2VTx?= M1TKcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
T47D MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuwNE0yODBizszN NIr0WnU1QCCq Mnf5SG1UVw>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
MCF7 NXrs[Yp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPHemF7OC1zMECwJO69VQ>? NXK3TWF7PDhiaB?= NE\qNZZFVVOR NVnDRYFscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M361WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
Hs683 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTuXYxwOC1zMECwJO69VQ>? MXq5OkBp MYHJR|UxRTF{OD65JO69VQ>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUmwO{c,OjR2OUW5NFc9N2F-
U87 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu2NE0yODByIN88US=> NUnVXpFXQTZiaB?= MnqzTWM2OD1zOD60OUDPxE1? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUmwO{c,OjR2OUW5NFc9N2F-
LNZ308 NVTlVFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33oPVAuOTByMDFOwG0> NVj0WZU2QTZiaB?= NHXaTI1KSzVyPUOyOk44KM7:TR?= M3W5d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
U87 NX[2fFJNSXCxcITvd4l{KEG|c3H5 MnvvNVAxKM7:TR?= M1X2e|Q5KGh? NVTQWoZ4TE2VTx?= NILpRYNqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 MofjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEG1PFYoRjJ2NEixOVg3RC:jPh?=
U251  M2DiRmFxd3C2b4Ppd{BCe3OjeR?= Mli4NVAxKM7:TR?= M{TDTFQ5KGh? NVXHPItjTE2VTx?= MlXTbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= M3TmZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEixOVg3Lz5{NES4NVU5PjxxYU6=
U251 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSxNlQhcA>? M{LxWWlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR|Mk[5OVQ9N2F-
U251 NU\pOYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PRelQ5KGh? NHXZXIlKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=> M2WzRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nBTlczKGh? MoHhTWM2OD15Mj60NwKBkcLz4pEJNU41PSEQvF2= Ml3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
U251 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpPVYhcA>? Mo[0TWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= M{jmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
T98G MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fhNFAuPzVyIN88US=> MmnUO|IwQTZiaB?= MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHLrUVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFA5OCd-MkSzNlQxQDB:L3G+
U251-MG NVL2coI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu5dI0xNThyMDFOwG0> NH7Tdo84OiCq Mlm2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2jmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzOlMxLz5{NEC5N|Y{ODxxYU6=
D54-MG MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXewMVgxOCEQvF2= M37kS|czKGh? M3fT[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{[zNEc,OjRyOUO2N|A9N2F-
SHG-44 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHrNVAuOjByIN88US=> MnHuPVYhcA>? NXu4dW1FUUN3ME25Mlc{KMLzIEKuNVIh|ryP MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373  NE\TeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNE0zODBizszN MXm5OkBp M3vi[GlEPTB;MUCuNVMhyrFiMT6wNkDPxE1? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
HT-29  NUTTeldsTnWwY4Tpc44hSXO|YYm= NXzWO2dSPTByIN88US=> NWf6[pV1OjRxNEigbC=> Mn\z[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? NFv0NHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzPFA3QCd-MkSwN|gxPjh:L3G+
PC-3  MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHK[ZAxNTJ3IN88US=> NV21b3M1PDhiaB?= MnzObY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m MojGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NE[5N|QoRjJ|N{S2PVM1RC:jPh?=
PC-3  NHfWXlZCeG:ydH;zbZMhSXO|YYm= NVXBXVBTOjVizszN NHvkV2E1QCCq M2LwcIlv\HWlZYOgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCyb4TlcpRq[XSnZDDifUBtgWOxcHXu[S=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2NkmzOEc,OjN5NE[5N|Q9N2F-
T98G NIrYcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHQNYY2OC12MECg{txO MY[xOFQhcA>? NUHySmZ2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NF;iZoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exOVQ6QSd-MkO3NVU1QTl:L3G+
U87-MG M{H1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG0VFkyODBiwsXN MoHwO|IhcA>? NI[5Z5BqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE NHjITYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olc5QCd-MkO2PVY4QDh:L3G+
U251-MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvJSGVsOTByINM1US=> Mo\1O|IhcA>? NGfrRoNqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE NF7lNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olc5QCd-MkO2PVY4QDh:L3G+
LNT-229 NXXEOm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmzMVExOCEQvF2= MYSyOEBp Mnz5bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{[zNkc,OjN4Nke2N|I9N2F-
T98G M3P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxNE04ODBizszN M4nTWVI1KGh? M1vyfolvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N|IoRjJ|Nk[3OlMzRC:jPh?=
U87  M4S1XWZ2dmO2aX;uJGF{e2G7 NXjlcnNPOTByINM1US=> MlzxN{Bp MYLlcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=> MmGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke0OlkoRjJ|Nk[3OFY6RC:jPh?=
HCT116 MojWSpVv[3Srb36gRZN{[Xl? MkDqNVAxKML3TR?= M2TZR|MhcA>? M{HwS4lv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w M2jqblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nk[3OFY6Lz5{M{[2O|Q3QTxxYU6=
HCT3-6 NGX3bIlHfW6ldHnvckBCe3OjeR?= NYPURW06OTByINM1US=> NV7NV5RIOyCq MXHpcoR2[2W|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{S2PUc,OjN4Nke0Olk9N2F-
U-87  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuwMVQxKM7:TR?= MVOxNkBl MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFeyS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OVczQSd-MkO2OFU4Ojl:L3G+
U-87  NFzkOoRCeG:ydH;zbZMhSXO|YYm= NFzqZpAxNTRyIN88US=> MkP4N{83KGR? M3LuNIlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87  Ml\HSpVv[3Srb36gRZN{[Xl? MXGwMVQxKM7:TR?= MUKzM|Yh\A>? M33mdolv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010 NHW5fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fD[|Qh\A>? MUfJR|UxRTJ{NjFOwG0> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
GB-SCC026 NUHvWZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXXOEBl M17wd2lEPTB;NUOuNUDPxE1? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
GB-SCC028 M4HEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID6eo01KGR? MojXTWM2OD1zNkeg{txO NYPjVWxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
U87 NU\I[Fg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXroTY1xPCCm MonKTWM2OD12NT6yJO69VQ>? M123R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkGyO|U2Lz5{M{[xNlc2PTxxYU6=
U87 stem cell MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnaOXJzPCCm NX22WYoyUUN3ME22Ok44KM7:TR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
TLX5 lymphoma NWr3ZVZnS3m2b4TvfIlkcXS7IHHzd4F6 M4jxcGlEPTBiPTC1JO69VQ>? M4XobFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
GM892 A M1f1dGN6fG:2b4jpZ4l1gSCjc4PhfS=> NEfPbHhKSzVyIE2gO{43KM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84PzN7MEC4K|44PzN7MEC4QE9iRg>?
TLX5 lymphoma Mn3LR5l1d3SxeHnjbZR6KGG|c3H5 NGPuc4hKSzVyIE2gOUDPxE1? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjR3OUCxOEc,OTJ2NUmwNVQ9N2F-
HCT116 NH\hRnVEgXSxdH;4bYNqfHliYYPzZZk> M17PZ|Qh\GG7cx?= NFjONIlKSzVyIE2gOE4{PCEQvF2= NXvZ[5hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NFA5ODNpPkG5PFAxQDB|PD;hQi=>
SNB75 NWnCcWpnSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2nOVFExKHWP M1\JO|I1KGi{cx?= M1nqZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17CO|Uh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?= Mor2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1NlYoRjJ{Mk[4OVI3RC:jPh?=
C6 MofiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NX\5UmV7OTByIIXN NVvZcppSPDhiaILz MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IILheEBEPiClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK|IHL5JI5mfXS{YXygdoVlKGmwY3;ydI9z[XSrb36gZZN{[Xl? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEWyOkc,OjJ{Nki1NlY9N2F-
SF295 MnLnRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWPLRmZPOTBidV2= MYCyOEBpenN? M1fufGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?= NYn2NYNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2OjZpPkKyNlY5PTJ4PD;hQi=>
U87 NHzjV25CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NH;ESYU2KGSjeYO= MmDXTWM2OCB;IES5JO69VQ>? NU\BN3JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NFg{QDlpPkKyOlA5Ozh7PD;hQi=>
U138MG M1jEfWN6fG:2b4jpZ4l1gSCjc4PhfS=> MonsOFghcHK| NX\VOFdlUUN3MDC9JFI3KM7:TR?= Mor2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkm2PFIoRjJ|ME[5OlgzRC:jPh?=
C6 NUjhfYVYS3m2b4TvfIlkcXS7IHHzd4F6 M2\LdFQ5KGi{cx?= MmXGTWM2OCB;IEO0JO69VQ>? MmLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkm2PFIoRjJ|ME[5OlgzRC:jPh?=
A2780 M{Lrc2FvfGm2dX3vdkBie3OjeR?= M{XCdlUh\GG7cx?= M4LHdGlEPTBiPTC4MlUh|ryP M1e2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEm1OlIxLz5{M{i5OVYzODxxYU6=
A2058 MV7BcpRqfHWvb4KgZZN{[Xl? MkjIOUBl[Xm| M1fy[mlEPTBiPTCzOU42KM7:TR?= NXvrSlJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4PVU3OjBpPkKzPFk2PjJyPD;hQi=>
SNB19 MmPlRY51cXS3bX;yJIF{e2G7 M2PDc|Uh\GG7cx?= MWXJR|UxKD1iM{eg{txO M3f0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEm1OlIxLz5{M{i5OVYzODxxYU6=
M8 M4O5XGFxd3C2b4Ppd{Bie3OjeR?= MVq1NEB1dyBzMECgeW0> M2HtVlQ5KGi{cx?= NX;5RXVxUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNPEBk\WyuczDhd5Nme3OnZDDhd{BieG:ydH;0bYMwdmWlcn;0bYMh[2WubIOgZZQhPTBidH:gNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O|c9N2F-
SK-MEL-30 Ml76RZBweHSxc3nzJIF{e2G7 NGTSfIwyODBidV2= NX[2VWx{PDhiaILz MUTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFONLV3FUE0{OCClZXzsd{Bie3Onc4Pl[EBieyCjcH;weI91cWNxbnXjdo91cWNiY3XscJMh[XRiMUCwJJVOKGGodHXyJFQ5KGi{czDifUBCWENvbHHi[Yxm\CCjbn7lfIlvKFZiYX7kJFcuSUGGIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{Bz\WyjdHn2[UB1dyClb370do9t M4PKXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK1PFc4Lz5{NEGyOVg4PzxxYU6=
SK-MEL-30 MkfaRZBweHSxc3nzJIF{e2G7 MYK1NEB2VQ>? NH3XZ2k1QCCqcoO= NV\3TIVtUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy|IHH0JFUxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u NInvSFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1 MVfBdI9xfG:|aYOgZZN{[Xl? MWSxNFAhfU1? MXK0PEBpenN? NWDhPG5CUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNUnQyKGOnbHzzJIF{e2W|c3XkJIF{KGGyb4D0c5Rq[y:wZXPyc5Rq[yClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK|IHL5JGFRSy2uYXLlcIVlKGGwbnX4bY4hXiCjbnSgO{1CSURic4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O|c9N2F-
MNT1 NVLXR21ISXCxcITvd4l{KGG|c3H5 M3PqWlUxKHWP MVK0PEBpenN? NF\OTnRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIF3OWFEh[2WubIOgZZN{\XO|ZXSgZZMh[XCxcITveIlkN26nY4LveIlkKGOnbHzzJIF1KDVyIIXNJIFnfGW{IES4JIhzeyCkeTDBVGMudGGkZXzl[EBidm6neHnuJHYh[W6mIEetRWFFKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrczDy[YxifGm4ZTD0c{Bkd262cn;s Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O|coRjJ2MUK1PFc4RC:jPh?=
A2780 MVjDfZRwfG:6aXPpeJkh[XO|YYm= Mm\OOUBl[Xm| NFu0TJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA2KGSjeYOgZpkhVVSWIHHzd4F6 NWXWVVhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA1OThpPkK0PVAxPDF6PD;hQi=>
A2780/CP70 M173N2N6fG:2b4jpZ4l1gSCjc4PhfS=> MmTIOUBl[Xm| MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBOVVJvZHXmbYNq\W62IHj1cYFvKEF{N{iwM2NRPzBiY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JG1VXCCjc4PhfS=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMESxPEc,OjR7MEC0NVg9N2F-
GBM 047T NVLhOJJDSW62aYT1cY9zKGG|c3H5 MX[yNEB2VQ>? MoXkNUB1dyB{IIfl[Yt{ MXPUeY1wemmlaXThcEBm\m[nY4SgbY4heGG2aXXueEBl\XKrdnXkJGdDVSByNEfUJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCwZYXyc5NxcGW{ZTDmc5Ju[XSrb36gZZQhOjBidV2gZYZ1\XJiMTD0c{AzKHenZXvzJIJ6KDOGIIT1cY9zKGOub37v[4VvcWNiYYPzZZk> NIXuc|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1OVU{Oid-Mk[zOVU2OzJ:L3G+
GBM 464T MVHBcpRqfHWvb4KgZZN{[Xl? NULpV416OjBidV2= M3vBbFEhfG9iMjD3[YVsew>? M3vOOnR2dW:{aXPp[IFtKGWoZnXjeEBqdiCyYYTp[Y51KGSncnn2[YQhT0KPIES2OHQh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIH7leZJwe3CqZYLlJIZwem2jdHnvckBifCB{MDD1UUBi\nSncjCxJJRwKDJid3Xlb5Mh[nliM1SgeJVud3JiY3zvco9o\W6rYzDhd5NigQ>? NHTKdIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1OVU{Oid-Mk[zOVU2OzJ:L3G+
U87MG NG[0U4FHfW6ldHnvckBie3OjeR?= M332OlMhcHK| M3fZZWlv\HWldHnvckBw\iCGTlGgZYxsgWyjdHnvckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBPPy2PZXTHJIZwem2jdHnvckBi\nSncjCzJIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?= Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4MUS0NVQoRjJ5NkG0OFE1RC:jPh?=
U87MG M2XVdGFvfGm2dX3vdkBie3OjeR?= MnGxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgc5J1cG:2b4DpZ4FtdHlieHXuc4dz[W[2ZXSgbY4hUGG{bHHuJI52\GVibX;1d4Uh[nKjaX6gZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIIPsc5chfHWvb4Kg[5Jwf3SqIHH0JFUxKHWvb3yvb4ctKGm4IHHkcYlvcXO2ZYLl[EBwdmOnIHThbYx6KG[xcjC1JIRigXN? NXW3WJM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
U87MG NFLKV5JCdnSrdIXtc5Ih[XO|YYm= NHT5TVdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BwenSqb4TvdIlk[WyueTD4[Y5w\3KjZoTl[EBqdiCKYYLsZY4hdnWmZTDtc5V{\SCkcnHpckBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDtc5V{\SC|dYL2bZZidCCjdDC1NEB2dW:uL3vnMEBqfiCjZH3pcol{fGW{ZXSgc45k\SCmYXnsfUBnd3JiNTDkZZl{ NX3OeWZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
MDCK MUnDfZRwfG:6aXPpeJkh[XO|YYm= MYGyOEBpenN? NETtbG1EgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?= NWTSbIxbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NlM5PzlpPkK3PFI{QDd7PD;hQi=>
MDCK M{jOWGN6fG:2b4jpZ4l1gSCjc4PhfS=> NWrG[5V{OjRiaILz MoC5R5l1d3SxeHnjbZR6KGGpYXnud5QhVUSFSzDj[YxteyCneIDy[ZN{cW6pIHPhdoJwdmmlIHHubJllemG|ZTC5JIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDt[YF{fXKnZDDh[pRmeiB5IHThfZMhfW6mZYKgbJlxd3irYzDjc45lcXSrb36gZpkhdWW2aIns[Y5mKGKudXWgd5RicW6rbnegZoF{\WRiY3zvco9o\W6rYzDzeZJ3cX[jbDDhd5NigQ>? Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O|koRjJ5OEKzPFc6RC:jPh?=
NB-EBc1 MWTxTHRUKGG|c3H5 MlT2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
C6 MYjDfZRwfG:6aXPpeJkh[XO|YYm= MmXZOEBl[Xm| MXjFR|UxKD1iMU[uOUDPxE1? MkHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
U87 NXTIS2h7S3m2b4TvfIlkcXS7IHHzd4F6 NHPz[lg4OiCqcoO= M17iUGlEPTBiPTCxPU4{QCEQvF2= NE[3fWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
SNB19 Mlz4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnL5O{Bl[Xm| MnXWS2k2OCB;IEO1Mlch|ryP MlHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
SNB19 NUHQcpBET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2jt[|ch\GG7cx?= MnXOS2k2OCB;IES1MlYh|ryP NYn1PIJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
U373 NWjtNmpqTnWwY4Tpc44h[XO|YYm= NFv5[XgyODBidV2= NHTW[Ys4OiCqcoO= NVPlZ41FUW6mdXP0bY9vKG:oIHTveYJt\SC|dILhcoRm\CCGTlGgZpJm[WtiaX6g[Y1xfHlidnXjeI9zKHS{YX7z[oVkfGWmIHj1cYFvKFV|N{OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h\2GvbXGtTFJCYCCuZY\lcEBifCBzMECgeW0h[W[2ZYKgO|IhcHK|IHL5JIZtd3diY4n0c41mfHK7 MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
Glioma MYTBcpRqfHWvb4KgZZN{[Xl? M4G4NGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGhwdW9ic3HwbYVveyBqaIXtZY4qKEeuaX;tZUBk\WyuczD4[Y5w\3KjZoTl[EBqdiC2cnHud4dmdmmlIH3veZNmKGG|c3Xzd4VlKGG|IH3veZNmKHO3co\peoFt M4PtVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856,TMZ
Smiles CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04610736 Not yet recruiting Drug: Temozolomide Oral Suspension Pediatric Cancer Orphelia Pharma|ClinSearch January 2021 Phase 1
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2
NCT04238819 Recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company November 9 2020 Phase 1
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) September 1 2020 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID